These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16265769)

  • 1. Editorial comment: boosted PIs and metabolism--it's not just the ritonavir.
    Moyle GJ
    AIDS Read; 2005 Oct; 15(10):531. PubMed ID: 16265769
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperlipidemia associated with the use of protease inhibitors.
    Smith JH; Martin GJ; Decker CF
    Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
    [No Abstract]   [Full Text] [Related]  

  • 3. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations.
    Cohen CJ
    AIDS Read; 2005 Oct; 15(10):528-32, 537-8. PubMed ID: 16265768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of high grade antiretroviral therapy on body fat distribution and metabolism].
    Schwenk A
    Zentralbl Gynakol; 1999; 121(11):552-3. PubMed ID: 10612226
    [No Abstract]   [Full Text] [Related]  

  • 6. Marked hyperlipidaemia on ritonavir therapy.
    Sullivan AK; Nelson MR
    AIDS; 1997 Jun; 11(7):938-9. PubMed ID: 9189227
    [No Abstract]   [Full Text] [Related]  

  • 7. Ritonavir, triglycerides, and pancreatitis.
    Perry RC; Cushing HE; Deeg MA; Prince MJ
    Clin Infect Dis; 1999 Jan; 28(1):161-2. PubMed ID: 10028103
    [No Abstract]   [Full Text] [Related]  

  • 8. Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia.
    Brown CA; Lesher JL; Peterson CM
    J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S86-9. PubMed ID: 15858517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid lowering therapy in patients with HIV infection.
    McBride M; Chin MT; Lee SM; Kelly B
    Lancet; 1998 Nov; 352(9142):1782-3. PubMed ID: 9848377
    [No Abstract]   [Full Text] [Related]  

  • 11. Gynecomastia and HAART.
    Post JJ
    AIDS Read; 2000 May; 10(5):314. PubMed ID: 10851722
    [No Abstract]   [Full Text] [Related]  

  • 12. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
    Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perinatal lopinavir + ritonavir: adrenal insufficiency.
    Prescrire Int; 2012 Mar; 21(125):71. PubMed ID: 22428190
    [No Abstract]   [Full Text] [Related]  

  • 14. Spinal epidural lipomatosis in a human immunodeficiency virus-positive patient receiving steroids and protease inhibitor therapy.
    Ebright JR; Stellini MA; Tselis AC
    Clin Infect Dis; 2001 Mar; 32(5):E90-1. PubMed ID: 11229864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.
    Sahali S; Chaix ML; Delfraissy JF; Ghosn J
    AIDS Rev; 2008; 10(1):4-14. PubMed ID: 18385776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M
    J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alopecia associated with ritonavir-boosted atazanavir therapy.
    Torres HA; Barnett BJ; Arduino RC
    AIDS; 2007 Jun; 21(10):1391-2. PubMed ID: 17545728
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.
    Lee GA; Rao MN; Grunfeld C
    Curr HIV/AIDS Rep; 2005 Feb; 2(1):39-50. PubMed ID: 16091248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.
    Sension M; Piliero PJ
    J Assoc Nurses AIDS Care; 2007; 18(1):36-47. PubMed ID: 17338984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.